Navigation Links
Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
Date:10/13/2011

of MDS.  Telintra has the potential for combining with other agents used to treat MDS.  Telintra has been well-tolerated with mostly grade 1 or 2 gastrointestinal side effects.

Background on MDS and Telintra

The myelodysplastic syndrome is a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis (blood cell production) involving one or more cell lineages (red blood cells, white blood cells or platelets) and a variable risk of transformation to acute myeloid leukemia.  It is estimated that MDS affects approximately 300,000 people worldwide. According to the American Cancer Society, 10,000–20,000 new cases of MDS are diagnosed each year in the United States, with survival rates ranging from six months to six years. MDS patients often require multiple blood transfusions to manage their disease.

Telintra has a novel mechanism of action that inhibits an enzyme called glutathione S-transferase P1-1, which leads to activation of Jun kinase, a key regulator of cellular growth and differentiation of blood precursor cells; and induces cancer cell death, or apoptosis, in human leukemia cell lines. Telintra is also being evaluated in a Phase 2 clinical study in Revlimid® refractory and resistant deletion 5q MDS patients.  Additional information about Telintra is available at www.telik.com.

About Telik, Inc.

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic disorders including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery tech
'/>"/>

SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
2. Telik Announces First Quarter 2011 Financial Results
3. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
4. Telik Announces Presentation and Webcast at 10th Annual Needham Healthcare Conference
5. Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance
6. Telik Announces Presentation and Webcast at 13th Annual BIO CEO & Investor Conference
7. Telik Announces Presentation at American Society of Hematology Annual Meeting
8. Telik Announces Third Quarter 2010 Financial Results
9. Telik Awarded $1.2 Million in Grants for Qualifying Therapeutic Development Projects
10. Telik Announces Publication of Review Focused on the Inhibition of the Enzyme GSTP1-1 as a Target for New Cancer Treatments
11. Telik Announces Publication of a Case Report of a Sustained Hematologic Response in Myelodysplastic Syndrome Following an Abbreviated Exposure to Oral Telintra(R) (Ezatiostat HCl)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Mallinckrodt plc (NYSE: MNK ) ... a share repurchase program. The open-ended authorization permits the ... plc ordinary shares. "Funding additional initiatives ... as we continue to pursue a range of focused ...
(Date:1/22/2015)... a privately held medical device company, announced today that ... ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to sell ... cancer in Japan . ViewRay,s technology, ... only MRI-guided radiation therapy system that images and treats ...
(Date:1/22/2015)... , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... focus on Omega-3 therapies for cardiovascular disease and overall health ... Company,s accomplishments in 2014 and its outlook for 2015 from ... Fellow Shareholders, We would like to take this ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... Prevention and Control Professionals Cite,Greatest Needs for ... More Environmental Services and Time-Saving High Tech ... than three out of four,(76%) infection prevention ... implemented additional measures to prevent the,transmission of ...
... Inc.,(Nasdaq: TRBN ) today announced presentation ... of Rheumatology meeting in Paris demonstrating that,repeat ... the,treatment of rheumatoid arthritis (RA), continues to ... Rheumatology (ACR) criteria and,consistent pharmacodynamic (PD) effects. ...
Cached Medicine Technology:Nationwide Progress Poll Reveals Increased Efforts by Hospitals to Control MRSA Infection 2Nationwide Progress Poll Reveals Increased Efforts by Hospitals to Control MRSA Infection 3Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting 2Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting 3Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting 4Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting 5
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
(Date:1/22/2015)... January 22, 2015 The federal court overseeing ... U.S. District Court, Southern District of West Virginia has upheld ... that proceeding’s first bellwether trial. In an Order dated January ... trial after finding that C.R. Bard had not proven a ...
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... annual revenues in the past three years. Today, the business ... , According to the sales manager of the company, this ... in 2015. This point can be reflected on the discounted ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 As ... of overall health care gains momentum worldwide, Rev. Eric ... HealthCare Chaplaincy Network (HCCN), will be the keynote ... spiritual care in Israel’s public health system. , The conference, ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... Scientists at Washington University School of Medicine in St. ... collection of proteins associated with the formation of actin ... cell,s ability to move is important to a broad ... cells pursue disease-causing invaders and how metastasizing cancer cells ...
... Donated, freeze-dried tendon grafts loaded with gene therapy ... a goal that has eluded surgeons to date. ... journal Molecular Therapy, a new graft technique may ... tendon tissue can reorganize as it heals. Such ...
... and improves ... customer ... subsidiary of Hays plc., one of the world,s leading specialist,recruitment ... processes and improve customer service., Hays stated that it ...
... in Bangalore, SUNNYVALE, Calif., Jan. 8 ... in the field of radiosurgery,announced today that Healthcare ... System for its new oncology center in,Bangalore, India. ... the first,CyberKnife System in India, expanding treatment access ...
... 8 Isolagen(TM), Inc. (Amex: ILE ),announced today ... Executive Officer of Isolagen, will present at the 26th ... 2:00 p.m.,(Pacific Time) / 11:00 a.m. (Eastern Time). The ... in San Francisco, California., The presentation will be ...
... Innovation with Beauty and Fitness Benefits From Too Faced ... Cosmetics and FUZE ... keeping beauty and,diet resolutions on track with a lip gloss that ... Faced FUZE Slenderize Guilt,Free Gloss! The first lip gloss on the ...
Cached Medicine News:Health News:Insights into cell movement likely to aid immune study, cancer research 2Health News:Insights into cell movement likely to aid immune study, cancer research 3Health News:Freeze-dried tendon implants prove effective in early studies 2Health News:Freeze-dried tendon implants prove effective in early studies 3Health News:Freeze-dried tendon implants prove effective in early studies 4Health News:Freeze-dried tendon implants prove effective in early studies 5Health News:Hays AG Integrates Authentidate(R) Signature Solution for Electronic Invoicing 2Health News:Hays AG Integrates Authentidate(R) Signature Solution for Electronic Invoicing 3Health News:Hays AG Integrates Authentidate(R) Signature Solution for Electronic Invoicing 4Health News:CyberKnife Radiosurgery Expands to India 2Health News:CyberKnife Radiosurgery Expands to India 3Health News:Isolagen Inc. to Present at the 26th Annual JPMorgan Healthcare Conference 2Health News:NEW! Too Faced FUZE Slenderize Guilt Free Gloss 2
The Hybrid Fixator consists of Three basic components: rings, wires, clamps. Final fracture reduction can be easily performed after frame assembly....
... pelvic fractures is one of the most ... surgeons. , ,Recognizing the difficulties when using ... internal fixation in these types of emergencies, ... a method to provide emergent reduction and ...
... external fixator designed for the quick stabilization ... humerus and forearm. , ,Indications include open ... the treatment of choice due to soft ... fully compatible with the Ace-Fischer System. The ...
... Stabilization with the Orthofix Pelvic Fixator ... inserted into the pelvis, and a fixator ... joined by a connector unit. A supplementary ... or in iliac crest applications. With this ...
Medicine Products: